Press Releases

VYNE Therapeutics Announces Private Placement of $88 Million

October, 30 2023

Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of $88 million, before deducting placement agent fees and offering expenses. The PIPE was led by Access…

Read More

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

October, 30 2023

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b clinical trial in the first half of 2024 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a…

Read More

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September, 06 2023

BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will also be available for 1-on-1 meetings with investors. Presentation Details Company Presentation: Monday, September 11, 2023 at 7:00 AM ET Speaker: David Domzalski, President and Chief Executive Officer Registration: Webcast Link The replay of the webcast will…

Read More

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August, 14 2023

Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication selection in Q4 2023 and initiating a Phase 1 trial in Q1 2024 BRIDGEWATER, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30,…

Read More

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May, 11 2023

Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of an IND filing by year-end 2023 BRIDGEWATER, N.J., May 11, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three months ended March 31, 2023 and provided…

Read More

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

May, 01 2023

Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in multiple validated preclinical models of autoimmune disease IND-enabling studies are ongoing in anticipation of an IND filing by year-end BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for…

Read More